| Browse All

InflaRx N.V. (IFRX)

Healthcare | Biotechnology | Jena, Germany | NasdaqGS
1.59 USD +0.39 (32.500%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 1.62 +0.03 (1.887%) ⇧ (April 17, 2026, 7:58 p.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 11:29 p.m. EDT

BargainBin / High Risk Churn: Despite a solid technical rally and interesting options positioning targeting a $2.50 breakthrough, the fundamental data reveals a capital-destructive biotech company with massive cash burn and negative earnings. The short-term momentum is weak on a fundamental basis as the 'bullish' option flow relies on speculative sentiment rather than earnings recovery. Long-term ownership is inadvisable given the deteriorating revenue apology and deteriorating fundamentals.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.070923
AutoETS0.077191
AutoARIMA0.077193
AutoTheta0.120559

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 51%
H-stat 1.23
Ljung-Box p 0.000
Jarque-Bera p 0.003
Excess Kurtosis 1.22
Attribute Value
Sector Healthcare
Debt to Equity Ratio 2.161
Market Cap 114,945,640
Forward P/E -2.10
Beta 1.51
Website https://www.inflarx.de

As of April 18, 2026, 11:29 p.m. EDT: Options market shows 'long-term call' positioning with significant Out-of-the-Money (OTM) Open Interest and volume at the $2.50 strike for April and July expirations, representing a 57% probability weight according to the data summary. This indicates speculators are positioning for a significant upside move towards the $2.50 resistance level, potentially viewing recent gains as a baseline for further expansion. However, the predicted direction from statistical models is negative (-12.5%), indicating a disconnect between speculative upside bets and predictive models suggesting continued downside. Implied Volatility (IV) remains relatively low for ATM strikes, suggesting low near-term premium pricing unless the $2.50 bullish thesis triggers a volatility spike.


Info Dump

Attribute Value
52 Week Change 0.3947369
Address1 Winzerlaer Str. 2
All Time High 53.1
All Time Low 0.711
Ask 1.61
Ask Size 6
Average Analyst Rating 1.6 - Buy
Average Daily Volume10 Day 1,544,770
Average Daily Volume3 Month 562,166
Average Volume 562,166
Average Volume10Days 1,544,770
Beta 1.506
Bid 1.57
Bid Size 6
Book Value 0.67839074
City Jena
Country Germany
Crypto Tradeable 0
Currency USD
Current Price 1.59
Current Ratio 4.132
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.67
Day Low 1.2
Debt To Equity 2.161
Display Name InflaRx
Earnings Call Timestamp End 1,711,022,400
Earnings Call Timestamp Start 1,711,022,400
Earnings Timestamp 1,773,923,400
Earnings Timestamp End 1,778,070,600
Earnings Timestamp Start 1,778,070,600
Ebitda -48,198,212
Ebitda Margins 0.0
Enterprise To Ebitda -1.44
Enterprise To Revenue 2,365.63
Enterprise Value 69,386,304
Eps Current Year -0.646
Eps Forward -0.7580524
Eps Trailing Twelve Months -0.8
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 0.94768
Fifty Day Average Change 0.64232004
Fifty Day Average Change Percent 0.6777816
Fifty Two Week Change Percent 39.47369
Fifty Two Week High 1.94
Fifty Two Week High Change -0.35000002
Fifty Two Week High Change Percent -0.18041238
Fifty Two Week Low 0.711
Fifty Two Week Low Change 0.879
Fifty Two Week Low Change Percent 1.2362869
Fifty Two Week Range 0.711 - 1.94
Financial Currency EUR
First Trade Date Milliseconds 1,510,065,000,000
Float Shares 60,014,640
Forward Eps -0.7580524
Forward P E -2.0974803
Free Cashflow -14,833,020
Full Exchange Name NasdaqGS
Full Time Employees 65
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -7,238,287
Has Pre Post Market Data 1
Held Percent Insiders 0.05979
Held Percent Institutions 0.27247998
Implied Shares Outstanding 72,292,859
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Long Name InflaRx N.V.
Market us_market
Market Cap 114,945,640
Market State CLOSED
Max Age 86,400
Message Board Id finmb_42434000
Most Recent Quarter 1,767,139,200
Net Income To Common -45,633,780
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 114,945,645
Number Of Analyst Opinions 7
Open 1.2
Operating Cashflow -35,314,328
Operating Margins 378.98343
Payout Ratio 0.0
Phone 49 3641 508 180
Post Market Change 0.029999971
Post Market Change Percent 1.8867906
Post Market Price 1.62
Post Market Time 1,776,470,317
Previous Close 1.2
Price Eps Current Year -2.4613004
Price Hint 4
Price To Book 2.343782
Price To Sales Trailing12 Months 3,918.913
Profit Margins 0.0
Quick Ratio 3.689
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key buy
Recommendation Mean 1.625
Region US
Regular Market Change 0.39
Regular Market Change Percent 32.5
Regular Market Day High 1.67
Regular Market Day Low 1.2
Regular Market Day Range 1.2 - 1.67
Regular Market Open 1.2
Regular Market Previous Close 1.2
Regular Market Price 1.59
Regular Market Time 1,776,456,001
Regular Market Volume 7,864,935
Return On Assets -0.45966998
Return On Equity -0.88633
Revenue Per Share 0.0
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 72,292,859
Shares Percent Shares Out 0.0339
Shares Short 2,452,174
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 2,672,487
Short Name InflaRx N.V.
Short Percent Of Float 0.040799998
Short Ratio 7.45
Source Interval 15
Symbol IFRX
Target High Price 24.140972
Target Low Price 2.0404801
Target Mean Price 8.968334
Target Median Price 7.112262
Total Cash 46,457,260
Total Cash Per Share 0.643
Total Debt 897,916
Total Revenue 29,331
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.8
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.08591
Two Hundred Day Average Change 0.5040901
Two Hundred Day Average Change Percent 0.46420982
Type Disp Equity
Volume 7,864,935
Website https://www.inflarx.de
Zip 7,745